PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder

NCT07121621 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Tours

Phase

Phase 4

Started

2025-09-01

Last updated

2025-08-13

Condition(s) studied

Attention Deficit Hyperactivity Disorder (ADHD)Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2)MethylphenidateObesity &Amp; Overweight

Investigational drug(s) / intervention(s)

PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.

PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.: The pharmacological intervention, which will be the same for all patients in the study, will consist in administering MPH at CIC 1415 (URHC of Tours) in the form of Prolonged Release at the patient's usual dosage, in the early morning. Pharmacokinetic study with repeated measurements at T0 (just before MPH administration) then T30 minutes, T1 hour, T2h, T3h, T4h, T6h, T8h (8 measurements) after MPH administration, in 15 patients with ADHD and obesity (BMI≥30 kg/m2) and in 15 patients with ADHD but without obesity (BMI\<30 kg/m2).

Study summary

PHACYLOB PHArmaCokinetics of methYLphenidate in adult patients with Attention-Deficit Hyperactivity Disorder (ADHD) : comparison between patients with and without OBesity.

Its aim is to determine whether, for a comparable treatment dose, there are differences in the pharmacokinetic of methylphenidate between ADHD patients with obesitý and ADHD patients but without obesitý. More specifically, we will assess whether blood concentrations of methylphenidate (MPH; long acting form) are significantly higher or lower in either group at different times of the day.

To meet this objective, we are conducting this pharmacokinetic clinical trial with blood sampling and repeated clinical measurements just prior to MPH administration (= at T0) and then, at different times after administration, i.e. at times (T): T 30 minutes, T 1 hour, T2h, T3h, T4h, T6h, T8h after MPH administration. As far as MPH is concerned, this is the usual treatment. However, we may hypothesize that the distribution in the body may differ according to weight: hence the interest of this study

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adults aged 18 and over * Diagnosis of ADHD by a psychiatrist, based on DSM-5 criteria (ADHD mixed form, predominantly inattentive or predominantly hyperactive/impulsive) * Treatment with methylphenidate LP (Ritaline) with a stable dosage for at least two weeks. * BMI inclusion criteria: (1) for obese group: BMI ≥ 30 kg/m2; (2) for non-obese group: BMI \< 30 kg/m2. * Participant affiliated to a social security scheme * Written consent signed by participant Exclusion Criteria: * Contraindications to methylphenidate treatment * Treatment with an oral or nasal decongestant vasoconstrictor; association with a non-selective MAOI antidepressant. * Treatment with a proton pump inhibitor within the last 2 weeks. * Severe cognitive impairment (clinical evaluation) * Severe alcohol use disorder, i.e. at least 6 DSM-5 criteria for substance use disorder (clinical evaluation) * Known prior renal impairment * Pregnant or breast-feeding women * Female patients of childbearing age without at least one acceptable contraceptive method (see definition in Appendix 1) * Patients under legal protection * Inability of the patient to self-assess the intensity of ADHD symptoms

Primary outcome measure(s)

Area under the curve (AUC) of blood concentrations of MPH and APP, its active metabolite, measured up to 8 hours (T0, T30 minutes, T1h, T2h, T3h, T4h, T6h, T8h) after MPH administration, compared between patients with and without obesity. — Anticipated recruitment period: 12 months / Duration of each subject's participation: 1 day / Total duration of research: 12 months and 1 day
The primary endpoint is the area under the curve (AUC) of blood concentrations of MPH and APP, its active metabolite, measured up to 8 hours (T0, T30 minutes, T1h, T2h, T3h, T4h, T6h, T8h) after MPH administration, compared between patients with and without obesity.

Trial sites (1)

Facility	City	Region	Status
Center Hospitalier Régional Universitaire of TOURS	Tours	Indre-et-Loire

More University Hospital, Tours trials in France

Communication Enhancement Among Ventilated Patients in Intensive Care Recruiting

Social Information Processing in Children: an ocUlo-pupillometric Tool for Standard Evaluation Recruiting

Assessment and Follow-up of Surgical Treatment of Hemivertebra in Children Recruiting

Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea Recruiting

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial Recruiting

Other trials for the same condition

Evaluation of the Care Provided to Patients Who Underwent Bariatric Surgery and Were Lost to Follow-up 5 Years After Surgery Recruiting

Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment Recruiting

Proof of Concept in the Prevention of Post-bariatric Sarcopenia: Simulated Activation of the "Gravitostat" Starting soon

Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07121621 on ClinicalTrials.gov ↗ ← All trials in France